XyloCor Therapeutics Partners with SmartCella for its Technology to Deliver XC001 as a Treatment of Refractory Angina
Shots:
- XyloCor & SmartWise (division of SmartCella) have signed a licensing agreement as per which the former gets worldwide rights to utilize SmartWise’s Extroducer Infusion Catheter System for catheter-based endocardial XC001 delivery
- SmartCella will receive upfront, clinical, regulatory & commercial milestones plus mid-single-digit royalties for a total of $130M on provision of catheters to XyloCor for its clinical & commercial use
- The P-I/II (EXACT) study of XC001 (delivered via minimally invasive surgery) in class II-IV angina patients (n=42) showed 43% without chest pain & with ordinary events post 6mos. and 58% free of angina episodes post 12mos. Its P-IIb study using Extroducer Delivery Catheter in coronary artery disease patients with refractory angina is planned
Ref: SmartCella | Image: SmartCella
Related News:- BMS’ Abecma Receives EC’s Approval for the Treatment of Relapsed/Refractory Multiple Myeloma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
